dacarbazine has been researched along with Genetic Predisposition in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arance, A; Cantarini, M; Dummer, R; Gutzmer, R; Kim, KB; Liszkay, G; Lorigan, P; Middleton, MR; Nyakas, M; Robert, C; Schadendorf, D; Spencer, S | 1 |
| Chicoine, MR; Dacey, RG; DeWees, TA; Dowling, JL; Huang, J; Kim, AH; Leuthardt, EC; Linette, G; Rich, KM; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD; Zipfel, GJ | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Clavreul, A; Lagarce, F; Messaoudi, K | 1 |
| Baer, C; Blaes, J; Claus, R; Felsberg, J; Galldiks, N; Grimm, C; Hartmann, C; Hau, P; Hertenstein, A; Hielscher, T; Meisner, C; Pietsch, T; Plass, C; Platten, M; Reifenberger, G; Roth, P; Sabel, MC; Sahm, F; Schackert, G; Schliesser, MG; Schmidt-Graf, F; Schramm, J; Vajkoczy, P; von Deimling, A; Weichenhan, D; Weiler, M; Weiß, EK; Weller, M; Westphal, M; Wick, W; Wiestler, B; Winkler, F | 1 |
| Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI | 1 |
| Federico, M; Gentile, M; Gobbi, P; Hohaus, S; Iannitto, E; La Sala, A; Luminari, S; Mammi, C; Marcheselli, L; Merli, F; Montanini, A; Morabito, F; Scalone, R; Stelitano, C; Voso, MT | 1 |
| Asano, Y; Fujii, M; Hatano, H; Ishii, D; Ito, M; Natsume, A; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J | 1 |
| Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A | 1 |
1 review(s) available for dacarbazine and Genetic Predisposition
| Article | Year |
|---|---|
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Design; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Glioblastoma; Humans; Molecular Structure; Phenotype; Signal Transduction; Structure-Activity Relationship; Temozolomide | 2015 |
2 trial(s) available for dacarbazine and Genetic Predisposition
| Article | Year |
|---|---|
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brazil; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; Europe; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Melanoma; Middle Aged; Mutation; Neoplasms, Unknown Primary; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; United States | 2013 |
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Bleomycin; Carboplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Female; Gene Deletion; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prednisone; Procarbazine; Prognosis; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2012 |
6 other study(ies) available for dacarbazine and Genetic Predisposition
| Article | Year |
|---|---|
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Gene Deletion; Genetic Predisposition to Disease; Glioma; Humans; Male; Middle Aged; Missouri; Prevalence; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioma; Humans; Kaplan-Meier Estimate; MicroRNAs; NF-kappa B; Phenotype; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Tolerance; RNA Interference; Temozolomide; Time Factors; Transcription, Genetic; Transfection | 2016 |
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Arachnoid; Brain; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Mutational Analysis; Gene Deletion; Genetic Predisposition to Disease; Genotype; Humans; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Oligodendroglioma; Pia Mater; Radiotherapy; Spinal Cord; Subarachnoid Space; Temozolomide; Treatment Outcome | 2009 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2007 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2008 |